How many 8-K filings has Cartesian Therapeutics, Inc. filed?

Cartesian Therapeutics, Inc. (RNAC) has 27 8-K (Current Event Report) filings on record, spanning Jan 2024 to Apr 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Cartesian Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Cartesian Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Cartesian Therapeutics, Inc. (RNAC) — 8-K Filings

All 8-K filings from Cartesian Therapeutics, Inc.. Browse 27 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (27)

8-K Filing — Apr 30, 2026
8-K Filing — Dec 18, 2025
Cartesian Therapeutics Files 8-K — Nov 13, 2025 Risk: low
On November 13, 2025, Cartesian Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events. No sp
Cartesian Therapeutics Files 8-K on Corporate Governance and Compensation — Oct 30, 2025 Risk: low
Cartesian Therapeutics, Inc. filed an 8-K on October 30, 2025, reporting on several key events including the departure of directors or certain officers, electio
Cartesian Therapeutics Announces Board and Executive Changes — Oct 21, 2025 Risk: medium
On October 15, 2025, Cartesian Therapeutics, Inc. reported changes in its board of directors and executive compensation arrangements. The filing details the dep
Cartesian Therapeutics Reports Board & Executive Changes — Oct 8, 2025 Risk: medium
On October 2, 2025, Cartesian Therapeutics, Inc. reported changes in its board of directors and executive compensation arrangements. The filing indicates the de
Cartesian Therapeutics Files 8-K on Shareholder Vote Matters — Jun 16, 2025 Risk: medium
Cartesian Therapeutics, Inc. filed an 8-K on June 16, 2025, reporting on matters submitted to a vote of security holders as of June 13, 2025. The filing indicat
Cartesian Therapeutics Files 8-K — May 30, 2025 Risk: low
On May 30, 2025, Cartesian Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 7495 New Horizo
Cartesian Therapeutics Board and Officer Changes Announced — Apr 29, 2025 Risk: medium
Cartesian Therapeutics, Inc. announced on April 29, 2025, a change in its board of directors. Specifically, the company reported the departure of certain office
Cartesian Therapeutics Files 8-K — Apr 8, 2025 Risk: low
On April 8, 2025, Cartesian Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and
Cartesian Therapeutics Files 8-K — Mar 3, 2025 Risk: low
Cartesian Therapeutics, Inc. filed an 8-K on March 3, 2025, reporting information under Regulation FD and including financial statements and exhibits. The compa
Cartesian Therapeutics Files 8-K — Jan 27, 2025 Risk: low
On January 27, 2025, Cartesian Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No
Cartesian Therapeutics Files 8-K — Jan 13, 2025 Risk: low
On January 13, 2025, Cartesian Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific materia
Cartesian Therapeutics Files 8-K — Dec 3, 2024 Risk: low
Cartesian Therapeutics, Inc. filed an 8-K on December 3, 2024, to report on other events and financial statements. The filing does not contain specific details
Cartesian Therapeutics to be Acquired by 03 Life Sciences — Sep 26, 2024 Risk: medium
Cartesian Therapeutics, Inc. announced on September 25, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transactio
Cartesian Therapeutics Files 8-K on Shareholder Vote Matters — Sep 23, 2024 Risk: medium
Cartesian Therapeutics, Inc. filed an 8-K on September 23, 2024, reporting on a submission of matters to a vote of security holders as of September 20, 2024. Th
Cartesian Therapeutics Files 8-K with Material Agreements & Officer Changes — Jul 2, 2024 Risk: medium
On July 1, 2024, Cartesian Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
Cartesian Therapeutics Announces Board Changes and Shareholder Votes — Jun 17, 2024 Risk: medium
Cartesian Therapeutics, Inc. announced on June 14, 2024, a series of significant corporate actions. These include the election of new directors, the appointment
Cartesian Therapeutics Files 8-K — May 22, 2024 Risk: low
On May 22, 2024, Cartesian Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and
Cartesian Therapeutics Files 8-K — Apr 22, 2024 Risk: low
Cartesian Therapeutics, Inc. filed an 8-K on April 22, 2024, reporting an event on April 19, 2024. The filing is under "Other Events" and does not specify any m
Cartesian Therapeutics Files 8-K: Regulation FD Disclosure — Apr 9, 2024 Risk: low
On April 8, 2024, Cartesian Therapeutics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial sta
Cartesian Therapeutics Appoints New Chief Medical Officer — Apr 1, 2024 Risk: medium
Cartesian Therapeutics, Inc. announced on March 26, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer. Dr. Miller previously served as Se
Cartesian Therapeutics Completes Merger with 03 Life Sciences — Mar 28, 2024 Risk: medium
On March 26, 2024, Cartesian Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the closing of its previously disclosed
Cartesian Therapeutics Terminates Material Agreement — Mar 14, 2024 Risk: medium
Cartesian Therapeutics, Inc. announced on March 8, 2024, the termination of a material definitive agreement. The company, formerly known as Selecta Biosciences
Cartesian Therapeutics Announces Executive and Board Changes — Mar 5, 2024 Risk: medium
On February 28, 2024, Cartesian Therapeutics, Inc. announced the departure of Dr. Robert J. B. Davies as Chief Medical Officer and the appointment of Dr. Sarah
Cartesian Therapeutics (RNAC) Faces Nasdaq Delisting for Low Bid Price — Jan 19, 2024
Cartesian Therapeutics, Inc. (RNAC) announced on January 17, 2024, that it received a delisting notice from The Nasdaq Stock Market LLC because its common stock
Cartesian Therapeutics Files 8-K for Corporate Communications — Jan 8, 2024
Cartesian Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to satisfy filing obligations related to written communications and soliciting materials

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX